Intensive care

The risk of cancer patients for septic complications is increased up to ten times when compared to noncancer patients. Cancer patients were excluded from participation in many RCTs on sepsis of the past. However, several subsequent observational studies could show that (1) suggested strategies derived from these RCTs were implemented also in cancer patients, (2) sepsis-associated mortality rates decreased markedly also in cancer patients, and (3) sepsis-associated mortality rates may not be different from mortality rates of sepsis patients without malignant diseases. In fact, highly specialized centers report hospital mortality rates of 43 % in neutropenic patients with severe sepsis or septic shock in more recent years.

Nearly every second ICU cancer patient with septic complications has recently received chemotherapy and/or is presenting with neutropenia. Both factors do not have an impact on mortality. In neutropenic sepsis patients, favorable outcomes are associated with the removal of central venous lines in the absence of another infection focus, the identification of a sepsis-causing microorganism, as well as with an antibiotic regimen combining an anti-pseudomonas broad spectrum ß-lactam with an aminoglycoside. In contrast, neutropenic sepsis is associated with increased mortality rates in case of higher degree of acute organ dysfunctions, need for IMV, as well as pulmonary or fungal infection.

In neutropenic sepsis, antimicrobial therapy corresponds to the treatment of neutropenic fever, unless the prior antimicrobial prophylaxis and/or therapy, or a manifest or suspected focus longs for modification, e. g. in case of pulmonary infiltrates (such as mold-active systemic antifungal therapy in lung infiltrates not typical for Pneumocystis pneumonia or lobar bacterial pneumonia, high-dose trimethoprim-sulfamethoxazole in infiltrates compatible with P. jirovecii). Several guidelines on the use of antimicrobials in neutropenic cancer patients with infection are available to support clinical decision-making. Even though using G-CSF formulations in neutropenic sepsis is not uncommon, there is no evidence for its efficacy and the use is not supported by guidelines. In contrast, observational studies point out that in case of pulmonary infection, respiratory impairment may be aggravated by G-CSF-associated neutropenia recovery, supposedly due to local inflammation and increased lung microvascular permeability.

Regardless of the reason for ICU admission, approximately 25 % of cancer patients present with at least one cancer-specific complication. The management of drug reactions to immuno- and/or chemotherapy, hyperleukocytosis, tumor lysis syndrome, malignancy-related airway obstruction, stem cell transplant-associated conditions, increased occurrences of certain electrolyte disturbances, such as hypercalcemia or SIADH, thrombotic microangiopathies, as well as thrombotic or bleeding diathesis warrant for close collaboration of intensivists with hemato/oncologists and colleagues from other disciplines.

Any suggested admission criteria can only offer a gross orientation and must be evaluated on a case-by-case basis with regard to its applicability. Based on the existing evidence, the following approach seems to be reasonable:

• A “full code management” without restrictions is advisable in patients in remission of their malignant disease, newly diagnosed malignancies with favorable life expectation (> 1 year), availability of curative therapeutic options (e. g. hematologic malignancies during induction or consolidation therapy), complications of autologous stem cell transplantation, in certain cases of low grade hematologic malignancies, in multiple myeloma with partial remission, as well as in patients with advanced stages of solid malignancies, if available therapeutic options still allow for long-term survival.
• The term “ICU trial” describes an initial “full code management” for three to five days followed by a thorough re-evaluation of the therapeutic strategy. This approach seems to be adequate in patients who do not fulfill the above stated criteria, but for whom the option of a potentially life-extending therapy is available. In patients of this category with at least two organ failure including IMV, Lecuyer et al. showed that no clinical sign at ICU admission correlates with hospital outcome. Only after the third ICU day the severity level of organ dysfunction differed between survivors and nonsurvivors. The mortality in these very ill patients was as high as 80 %. No patient requiring an additional intensive care therapy measure (intubation, renal replacement therapy vasopressors) after the third ICU day survived.

According to the available literature, patients with no life-extending therapy option for their underlying malignant disease, with uncontrolled or refractory graft-versus-host-disease after allogeneic stem cell transplantation, unfavorable cancerrelated life-expectation (< 1 year), and patients who were bedridden most of the time within the last three months should not receive aggressive ICU therapies. However, ICU admissions for management of a specific acute problem together with primary therapy limitations (such as do-notintubate orders) may be suitable in selected patients.

Several questions in the context of critically ill cancer patients remain unanswered:

•  How effective is communication and collaboration between intensivists and hemato/oncologists with regard to clinical decision-making?
•  What is the impact on outcome if no hemato/ oncologist is available due to the institutional structure?
•  What are the specific needs of critically ill cancer patients’ families?
•  How can we optimize the transition from full code ICU management to palliative care, if indicated?
•  Early ICU admissions seem to be associated with a favorable outcome in cancer patients with ARF. However, if this applies to other organ dysfunctions remains unclear. Moreover, a recent publication suggested that treating patients with acute leukemia with hematological risk of early death in the ICU even in the absence of a manifest organ failure is associated with improved survival.
•  How can we establish effective structures to identify patients in the wards who would profit from ICU admission?
•  How safe and effective is the administration of intensive care measures in the setting of a normal ward?
•  What would be the benefits of hemato/oncologic intermediate care units?

The mortality rates of cancer patients with ARF and septic complications correlate with the number of treated cases per year per respective ICU (volume dependency). So-called high-volume ICUs are more likely to be part of a tertiary care or university hospital with an affiliated department of hemato/ oncology. This fact needs to be considered whenever assessing the research results related to the subject, as these are usually derived from highly specialized centers. Even though various data reported from nonspecialized centers are promising, some authors still report on disproportionally high mortality rates. Given the fact that every sixth to eighth European ICU patient suffers from an underlying malignant disease, educational measures should be encouraged to ensure optimal treatment of these patients in case of critical illness. In complex cases, however, transfer of patients to an expert center should be evaluated.

 The authors of this review suggest establishing local structures including joint educational sessions on the recent advances of cancer treatments and intensive care medicine, ICU admission policies for orientation, joint evaluation of ICU transfer candidates, daily interdisciplinary rounds of critically ill ICU cancer patients, as well as debriefing sessions subsequent to the treatment of challenging cases. Eventually, including basic elements of intensive care, as well as specific aspects of hematologic and oncologic patients into the curricula of future cancer specialists and intensivists, will benefit the patients.